Henry McCusker's  Instablog

Henry McCusker
Send Message
Analyst, Journalist and Publisher ... Henry enters his tenth (10) year at Scimitar Equity -Regenerative Medicine Investors which aggregates, curates and creates bottom-line content weeding of regenerative medicine and cell therapy news to provide a customized, vetted selection of relevant and... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
  • Another Step Forward Aastrom Biosciences (NASDAQ:ASTM) 1 comment
    Dec 9, 2009 5:27 PM

    Aastrom is a leader in regenerative medicine developing autologous cell products for the treatment of severe, chronic cardiovascular diseases. ASTM’s proprietary Tissue Repair Cell (NYSE:TRC) technology expands the numbers of stem and early progenitor cells from a small amount of bone marrow collected from the patient.

    Updating our blogs on 10/25/09,  11/9/09 and 11/16/09:

    NASDAQ Hearings Panel Granted an Exception Period to Aastrom based on its request to remain listed on the NASDAQ Stock Market on 11/9/09 until 3/31/10, subject to certain conditions:

    • The Panel’s determination letter, dated 12/8/09, states that Aastrom must meet the $1.00 minimum closing bid price requirement for a minimum of 10 consecutive business days prior to 3/31/10 in order to remain listed after such date,
    • The Panel may, in its discretion, require ASTM to maintain a minimum closing bid price of at least $1.00 per share for a period in excess of 10 consecutive business days (but generally no more than 20 consecutive business days) before determining that Aastrom has demonstrated the ability to maintain long-term compliance.

    Bottom Line:  In the determination letter, the Panel also acknowledged:

    • ASTM’s commitment to implement a reverse stock split, assuming that is necessary to regain compliance,
    • With unanimous consent of the Board of Directors, ASTM has filed a definitive proxy that includes a proposal seeking shareholder approval to affect a reverse stock split,
    • The Panel has reserved the right to reconsider its decision at any time and Aastrom must provide the Panel notice of any significant events during the exception period.

Back To Henry McCusker's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • Gerryy
    , contributor
    Comments (2) | Send Message
    In doing some background work to see if I wanted to invest, I came across the following press release on yahoo -


    Press Release Source: Aastrom Biosciences, Inc. On Monday November 16, 2009, 6:50 am EST


    I had to read the results section a few times to figure out what it meant. I must admint that I sometimes do have to read things more than once to 'get it', but when I finally realize that the trouble I had in understanding was not only my capacity to understand, but what appears to be an attempt to keep me from truly understanding, I become annoyed and do some writing of my own, which follows below in the form of a note I sent to Aastrom. (I could have been more clear in my note as well). It seems to me that the press release was designed to widen a desired gulf between results of those taking the treatment vs. those in the control group. The results could have been presented in a tabular format, but of course, that would have made the outcomes clear, rather than a bit muddy.
    My note to Aastrom-


    I found the wording of the release confusing because it expressed test results of the group taking the treatment in terms of the number of participants who improved, while the test results of the control group were reported in terms of the number who did not improve, somewhat begging the question as to whether others in the control group improved or remained as they were initially categorized. Sorry for the suggestion, but was the method used to report the control group results designed to avoid saying that some participants in this group also improved? Of course we all hope that would in any case be the result, but if the press release was designed to emphasize the benefits of the treatments effects, confidence in its 'facts' will be hard to digest
    23 Dec 2009, 04:03 PM Reply Like
Full index of posts »
Latest Followers


  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.